Thorne HealthTech is highlighting the results of a study suggesting the company's OneDraw blood collection device is successful in testing for COVID-19 antibodies. Results were published on May 10 in the Journal of Telemedicine and Telecare.
The company said that 99.9% of samples received were successfully processed in the 4,000-patient study. The study was led by the Medical Research Council Epidemiology Unit at the University of Cambridge in the U.K. to evaluate the prevalence of previous infection with COVID-19 using remote blood samples.
Thorne is studying additional applications of the OneDraw device, including the use of its plasma separation cartridge. Long term, the company said it believes the device will contribute to healthy aging, longevity, and precision wellness. It also plans to pilot the OneDraw device in its Thorne Lab clinic.